American Journal of Cardiology
Volume 103, Issue 12 , Pages 1635-1640 , 15 June 2009

Feasibility and Safety of Prehospital Administration of Bivalirudin in Patients With ST-Elevation Myocardial Infarction

  • Maria Sejersten, MD

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author: Tel.: +4522-30-16-56; fax: +4535-45-26-48
    • ,
  • Søren Loumann Nielsen, MD

      Affiliations

    • Mobile Emergency Care Unit, Capital Region of Denmark, Copenhagen, Denmark
    • ,
  • Thomas Engstrøm, MD, PhD, DMSc

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    • ,
  • Erik Jørgensen, MD

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    • ,
  • Peter Clemmensen, MD, DMSc

      Affiliations

    • Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

Received 27 October 2008 ,Revised 10 February 2009 ,Accepted 10 February 2009.

References 

  1. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al 2007 Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation. 2008;117:296–329
  2. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–2945
  3. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, et al A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003;349:733–742
  4. Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, et al Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205–2217
  5. Van't Hof A, Ten Berg J, Heestermans T, Dill T, Funck R, van Werkum W, et al Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008;372:537–546
  6. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. J Am Med Assoc. 2003;289:853–863
  7. Lincoff AM, Kleiman NS, Kereiakes DJ, Feit F, Bittl JA, Jackman JD, et al Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. J Am Med Assoc. 2004;292:696–703
  8. Singh S, Molnar J, Arora R. Efficacy and safety of bivalirudin versus heparins in reduction of cardiac outcomes in acute coronary syndrome and percutaneous coronary interventions. J Cardiovascular Pharmacol Ther. 2007;12:283–291
  9. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–2216
  10. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. J Am Med Assoc. 2007;298:2497–2506
  11. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, et al Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–2230
  12. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the bivalirudin angioplasty study. Am Heart J. 2001;142:952–959
  13. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, et al Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation. 1993;87:1622–1629
  14. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, et al Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764–775
  15. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med. 2001;345:1473–1482
  16. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008;31:I17–I20
  17. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, et al Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008;31:I2–I9
  18. Lev EI, Kornowski R, Vaknin-Assa H, Brosh D, Fuchs S, Battler A, et al. Effect of clopidogrel pretreatment on angiographic and clinical outcomes in patients undergoing primary percutaneous coronary intervention for ST-elevation acute myocardial infarction. Am J Cardiol. 2008;101:435–439
  19. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22:105S–111S
  20. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, et al Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354:1464–1476
  21. Moscucci M, Fox KA, Cannon CP, Klein W, Lopez-Sendon J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary events (GRACE). Eur Heart J. 2003;24:1815–1823
  22. Wong P, Robinson A, Shaw S, Rodrigues E. Long term clinical outcome and bleeding complications among hospital survivors with acute coronary syndromes. Postgrad Med J. 2006;82:224–227
  23. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930–935
  24. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, et al Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907–919
  25. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol. 2003;42:1739–1746
  26. Stella JF, Stella RE, Iaffaldano RA, Stella DJ, Erickson KW, Bliley RC. Anticoagulation with bivalirudin during percutaneous coronary intervention for ST-segment elevation myocardial infarction. J Invasive Cardiol. 2004;16:451–454
  27. Abildstrøm SZ, Rasmussen S, Kruse M, Madsen M. Dansk Hjerteregister–Årsberetning. 2nd ed.. Copenhagen: Statens Institut for Folkesundhed; 2005;
  28. Cohen DJ, Lincoff AM, Lavelle TA, Chen HL, Bakhai A, Berezin RH, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol. 2004;44:1792–1800

 This study was supported by Carl og Katy Kajsings Legat, Copenhagen; C.C. Klestrup og hustru Henriette Klestrups Mindelegat, Copenhagen; Danske Lægers Forsikring under Codan/SEB Pension, Copenhagen; Direktør Emil Hertz og hustru Inger Hertz' Fond, Copenhagen; Eva og Henry Frænkels Mindefond, Copenhagen; Købmand Sven Hansen og hustru Ina Hansens Fond, Sorø; Lippmann Fonden, Copenhagen; and Frimodt-Heineke Fonden, Klampenborg, Denmark.

PII: S0002-9149(09)00596-7

doi: 10.1016/j.amjcard.2009.02.015

American Journal of Cardiology
Volume 103, Issue 12 , Pages 1635-1640 , 15 June 2009

Article Tools

* Image Usage & Resolution